
NORTHWEST BIOTHERAPEUTICS INC
70
Recent developments include financing deals announced in late 2024 and regulatory approvals received in 2022, alongside ongoing legal actions.
- Northwest Biotherapeutics announced a $5 million convertible note and a $50 million standby financing deal in December 2024 to support its operations [N1].
- The company received final approval of its Pediatric Investigation Plan from the UK MHRA in August 2022, advancing its regulatory progress [N1].
- Northwest Biotherapeutics initiated a lawsuit against Citadel Securities as reported in December 2022, indicating ongoing legal challenges [N1].
Northwest Biotherapeutics Inc operates in the biotechnology sector, developing immunotherapy products aimed at treating cancers such as brain tumors. The company’s business model centers on clinical development and regulatory approvals to advance its therapeutic candidates. Recent SEC filings reveal ongoing financial challenges with significant net losses and liquidity constraints. The company has pursued financing arrangements to support operations and has achieved regulatory milestones such as MHRA approval of its Pediatric Investigation Plan. Legal actions and risk disclosures are part of its operational context.
Northwest Biotherapeutics Inc is a biotechnology company focused on immunotherapy treatments, including brain tumor vaccines. The company reported a net loss of $28.76 million and revenue of $284,000 in recent quarters, with limited liquidity as of September 30, 2026. It has engaged in financing activities including convertible notes and standby financing deals. Regulatory progress includes final approval of a Pediatric Investigation Plan from the MHRA. Risk factors are disclosed in the 2025 10-K filing. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The company’s regulatory progress, including MHRA approval of its Pediatric Investigation Plan, supports its clinical development pathway. Financing deals such as convertible notes and standby facilities provide capital to sustain operations. If clinical trials demonstrate efficacy and safety, the company could advance its immunotherapy products toward commercialization. Continued regulatory approvals and successful financing could enhance operational stability and development momentum.
Northwest Biotherapeutics faces significant liquidity challenges with a current ratio of 0.03 and cash ratio of 0.01 as of September 30, 2026. The company reported substantial net losses and limited revenue, indicating ongoing financial strain. Dependence on external financing and the inherent risks of clinical development and regulatory approval present material risks. Legal disputes and competitive pressures in the biotech sector add to operational uncertainties.
Northwest Biotherapeutics’ moat is primarily based on its proprietary immunotherapy technology and clinical development pipeline targeting brain tumors. Regulatory approvals such as the Pediatric Investigation Plan from MHRA contribute to its competitive positioning. However, the company faces typical biotech sector risks including clinical trial outcomes, regulatory hurdles, and capital requirements. Its moat is contingent on successful clinical and regulatory execution and the ability to secure ongoing financing.
• Liquidity Risk: The company’s current ratio of 0.03 and cash ratio of 0.01 as of September 30, 2026, indicate limited liquidity to cover short-term liabilities.
• Clinical and Regulatory Risk: Success of immunotherapy products depends on clinical trial outcomes and regulatory approvals, which are inherently uncertain.
• Financing Risk: The company relies on external financing such as convertible notes and standby financing to fund operations, which may dilute shareholders or be unavailable.
• Legal Risk: Ongoing litigation, including a lawsuit against Citadel Securities, may result in financial or reputational impacts.
Business trends: The company continues to focus on advancing its immunotherapy clinical pipeline with regulatory approvals and financing activities.
Execution milestones: Achieving regulatory approvals such as the MHRA Pediatric Investigation Plan and securing convertible note and standby financing deals.
Key risks: Liquidity constraints, clinical trial and regulatory uncertainties, reliance on external financing, and ongoing legal disputes.
High visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Northwest Biotherapeutics Inc is a biotechnology company focused on developing immunotherapy treatments, including brain tumor vaccines.
- The company reported revenue of $284,000 for the quarter ended March 31, 2024, according to its 10-Q filing.
- As of September 30, 2026, the company had cash and cash equivalents of $725,000 and current assets totaling $2,428,000.
- Current liabilities as of September 30, 2026, were $90,936,000, resulting in a low current ratio of 0.03 and a cash ratio of 0.01, indicating liquidity challenges.
- The company reported a net loss of $28,762,000 for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.02 per share.
- Northwest Biotherapeutics announced a $5 million convertible note and a $50 million standby financing deal in December 2024.
- The company received final approval of its Pediatric Investigation Plan (PIP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in August 2022.
- Northwest Biotherapeutics has engaged in litigation against Citadel Securities as of December 2022.
- Risk factors applicable to the company are detailed in its 2025 Form 10-K filing.
- The company’s recent news coverage includes business developments and financing activities but no direct mention of revenue growth or profitability improvements.
- Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Generated 2026-11-14
- S1 | 2026-04-15 | 10-K
- S2 | 2026-11-13 | 10-Q
- N1 | 2026-11-14 | www.nasdaq.com | The Blockchain Boom Is Still Happening Behind the Scenes. These 3 Growth Stocks Will Benefit. | https://www.nasdaq.com/articles/blockchain-boom-still-happening-behind-scenes-these-3-growth-stocks-will-benefit
- N2 | 2026-11-14 | www.nasdaq.com | Jamie Dimon Just Said 5 Words Blocking Outside AI Agents From JPMorgan Accounts: "You Don't Want Rogue Agents." Here's Why That Security Stance Matters for JPM and Its Tech Rivals. | https://www.nasdaq.com/articles/jamie-dimon-just-said-5-words-blocking-outside-ai-agents-jpmorgan-accounts-you-dont-want
- N3 | 2026-11-14 | www.nasdaq.com | 4 Dividend Stocks Yielding 4% or More to Buy Before the End of November | https://www.nasdaq.com/articles/4-dividend-stocks-yielding-4-or-more-buy-end-november
- N4 | 2026-11-14 | www.nasdaq.com | Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech? | https://www.nasdaq.com/articles/regeneron-has-16-billion-net-cash-and-trades-near-20-times-earnings-it-cheapest-big
- N5 | 2026-11-14 | www.nasdaq.com | Why a Rising TSMC Challenger Could Reshape the Chip Foundry Landscape | https://www.nasdaq.com/articles/why-rising-tsmc-challenger-could-reshape-chip-foundry-landscape
- N6 | 2026-11-14 | www.nasdaq.com | Not Only Did President Donald Trump Fail to Keep His Social Security Promise, but He May Have Accelerated the Program's Path to Insolvency | https://www.nasdaq.com/articles/not-only-did-president-donald-trump-fail-keep-his-social-security-promise-he-may-have
- N7 | 2026-11-14 | www.nasdaq.com | Prediction: ASML Will Join the $800 Billion Club in 2029 | https://www.nasdaq.com/articles/prediction-asml-will-join-800-billion-club-2029
- N8 | 2026-11-14 | www.nasdaq.com | Advanta Receives Key Approvals For Misr Hytech Acquisition | https://www.nasdaq.com/articles/advanta-receives-key-approvals-misr-hytech-acquisition
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


